Boehringer Ingelheim invests 65 million euros in vaccines against avian influenza
Boehringer Ingelheim said it intends to invest additional 65 million euros in the development of vaccines against avian influenza.
Six months after the opening of the new French headquarters of the Center for Animal Health in Lyon-Gerland Biological University, Boehringer Ingelheim said it was going to invest additional 65 million euros in the development of vaccines against avian influenza.Boehringer Ingelheim will invest 65 million euros in vaccines against avian influenza.The new large project of Boehringer Ingelheim will be implemented in the new three-story building of the center, designed to develop and distribute vaccines against avian influenza.The creation of the center began in March 2018, and it is expected that the first vaccines will be available in the spring of 2020 and will be intended for the world market, with the exception of the United States.
Fifteen months after the acquisition of Merial (Sanofi) in January 2017, new investments will lead to the creation of 42 new jobs, mainly consisting of qualified employees (service managers, production technicians).
Over the past 22 years, more than 350 million euros have been invested in the development of vaccines at the Lyon-Gerland Biological University.These new investments will eventually lead to a triple increase in the production of inactivated vaccines.
Source: meatinfo.ru
